TUCSON, Ariz., September 3, 2026 — Critical Path Institute® (C-Path) is deeply saddened to announce the passing of Peter Barton Hutt, a longtime member of C-Path’s Board of Directors, on September 2, 2026.Continue reading
Category Archives: AZBio News
AZBio offers ASU tuition scholarships to Member employees and dependents
Employees of AZBio Member Companies and their dependents can now get a 15% scholarship for over 400 undergraduate degrees, graduate degrees, and certificates offered by ASU Online.
Learn more at AZBio.org/InStrideContinue reading
Bright Path Labs Moves into the Fast Lane
Bright Path is Transforming America’s Access to Essential Medicines..
Bright Path will be honored with an AZBio Fast Lane Award on Oct. 7, 2026 at the Phoenix Convention Center at the 23 annual AZBio Awards.Continue reading
Mayor Gallego Celebrates Flinn Foundation’s Legacy of Leadership and Philanthropy
Global Philanthropy Leadership Award recognizes an enduring commitment to strengthening Arizona and investing in its futureContinue reading
ALIS Acquires Ella® and elbi® Technologies, Expanding AI-Powered Dementia and Behavioral Care Support for Senior Living
Acquisition puts a dementia expert in every caregiver’s pocket to help reduce high-risk behavioral incidents and reliance on psychotropic medicationsContinue reading
AZBioPEERS: Public Policy for the Health Innovation Founder
Public policy decisions can directly influence how health innovations are funded, regulated, reimbursed, adopted, and accessed by patients. This AZBioPEERS video features a discussion hosted by Joan Koerber-Walker, AZBio CEO, with Steve Potts, CEO of Breakthru Medicine, and Tom Eisiminger, Jr., President and CEO of Regenesis Medical, on why policy engagement matters for health innovation entrepreneurs. Panelists will share perspectives on how founders and CEOs can stay informed, build relationships, and make their voices heard on issues that affect company growth, patient access, and Arizona’s broader life science ecosystemContinue reading
Critical Path for Parkinson’s Announces Milestone Publication Highlighting FDA Support for Novel Biomarker to Advance Precision Medicine Strategies
Journal of Parkinson’s Disease recognizes a decade of collaborative progress culminating in regulatory endorsement for biomarkers to enable early interventionContinue reading
Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer’s disease assessment across primary and specialty care
- First and only FDA-cleared, single-biomarker blood test supporting both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings
- The test delivers consistency across clinical settings by using the same validated cutoffs in primary and specialty care
- Designed for broad implementation across Roche’s installed base of more than 4,500 cobas laboratory instruments in the U.S. supporting access through existing laboratory infrastructureContinue reading
AZBio Member Spotlight – Remedy Medical Manufacturing
Based in Arizona, Remedy Medical Manufacturing is a Contract Development and Manufacturing Organization filling a critical gap between the lab and market for companies of all sizes, keeping life-saving technologies moving forward on their path to commercialization.Continue reading
Your Feedback Wanted on Proposed Changes to Reporting Peer Review Outcomes for Applications
NIH is seeking public comment on proposed changes to the reporting of peer review outcomes for grant applications (NOT-OD-26-088). Comments will be accepted electronically here until October 13, 2026.
These proposed updates are intended to strengthen alignment with the NIH Unified Funding Strategy which prioritizes scientific merit and reinforces the central role of peer review in NIH funding decisions. Under this framework, NIH Institutes, Centers, and Offices (ICOs) should consider peer review information in its entirety.Continue reading